Emerging interleukin targets in the tumour microenvironment: implications for the treatment of gastrointestinal tumours.

Lindsay Kathleen Dickerson, Jason A Carter, Karan Kohli, Venu G Pillarisetty

Gut 2023 Aug

filter terms:

The effectiveness of antitumour immunity is dependent on intricate cytokine networks. Interleukins (ILs) are important mediators of complex interactions within the tumour microenvironment, including regulation of tumour-infiltrating lymphocyte proliferation, differentiation, migration and activation. Our evolving and increasingly nuanced understanding of the cell type-specific and heterogeneous effects of IL signalling has presented unique opportunities to fine-tune elaborate IL networks and engineer new targeted immunotherapeutics. In this review, we provide a primer for clinicians on the challenges and potential of IL-based treatment. We specifically detail the roles of IL-2, IL-10, IL-12 and IL-15 in shaping the tumour-immune landscape of gastrointestinal malignancies, paying particular attention to promising preclinical findings, early-stage clinical research and innovative therapeutic approaches that may properly place ILs to the forefront of immunotherapy regimens. © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Citation

Lindsay Kathleen Dickerson, Jason A Carter, Karan Kohli, Venu G Pillarisetty. Emerging interleukin targets in the tumour microenvironment: implications for the treatment of gastrointestinal tumours. Gut. 2023 Aug;72(8):1592-1606